👪

Inheritance

1

Autosomal recessive HP:0000007

Biallelic CERS1 variants. The founding report described four affected siblings homozygous for a nonsynonymous variant in a consanguineous family.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:24782409 SUPPORT Human Clinical

"We identified a homozygous nonsynonymous mutation in CERS1, the gene encoding ceramide synthase 1, in 4 siblings affected by a progressive disorder with myoclonic epilepsy and dementia"

Establishes the recessive architecture and the size of the founding pedigree.

◈

Mechanistic Hypotheses

2

er_stress_apoptosis_model

er_stress_apoptosis_model CANONICAL

Evidence balance 1 support

Loss of C18-ceramide destabilizes ER homeostasis in neurons, the unfolded protein response is engaged, and sustained ER stress drives apoptotic neuronal loss. This is the account the founding study advanced and it fits the enzyme's ER localization. Its evidential base is a knockdown in a neuroblastoma line rather than patient or model neurons.

Show evidence (1 reference)

PMID:24782409 SUPPORT In Vitro

"downregulation of CerS1 in a neuroblastoma cell line triggers ER stress response and induces proapoptotic pathways"

The experimental basis for the model.

sphingolipid_membrane_homeostasis_model

sphingolipid_membrane_homeostasis_model ALTERNATIVE

Evidence balance 2 support

The primary defect is a broader failure of neuronal sphingolipid homeostasis rather than an ER stress response specifically: brain sphingolipid biosynthesis falls and steady-state sphingolipid and sphingoid base levels shift dramatically, and it is that altered membrane and signalling lipid composition - evidenced by the lipofuscin and ubiquitylated protein accumulation - that degrades neurons over time. The mouse data speak more directly to this account than to the ER stress one, since they measure brain lipids and show a storage phenotype rather than showing an unfolded protein response. The two are not exclusive and may be sequential.

Show evidence (2 references)

PMID:21625621 SUPPORT Model Organism

"a reduction in sphingolipid biosynthesis in the brain and dramatic changes in steady-state levels of sphingolipids and sphingoid bases"

The brain-wide lipid disturbance this account is built on.

PMID:21625621 SUPPORT Model Organism

"it remains largely unclear whether sphingolipid changes in these diseases are pathological events or homeostatic responses"

Curated PARTIAL, and quoted deliberately against the hypothesis it belongs to: the same paper states that the causal direction of sphingolipid changes in neurodegeneration is unresolved in general.

?

Discussions and Knowledge Gaps

3

Does ER stress and proapoptotic signalling after CerS1 knockdown in a neuroblastoma line report what happens in a CERS1-deficient human neuron?

HUMAN MODEL MISMATCH OPEN mismatch_er_stress_rests_on_a_neuroblastoma_knockdown

Attached to

pathophysiology#Endoplasmic Reticulum Stress Response

This is the entry's weakest link and it sits in the middle of the canonical mechanism. The claim that loss of CerS1 causes ER stress and apoptosis comes from acute downregulation in a tumour-derived cell line. Three gaps separate that from the disease. Neuroblastoma cells are proliferating and transformed, with a lipid metabolism unlike a post-mitotic neuron's. Acute knockdown is not the same as lifelong reduced activity, and an acute drop is far more likely to provoke a stress response than a chronic set-point change. And the human variant reduces C18-ceramide rather than abolishing the enzyme, while the knockdown removes it. The mouse work, which is the better model, measures lipids and storage material but does not report an unfolded protein response - so the ER stress account is not independently corroborated.

Proposed experiments

Unfolded protein response markers in patient-derived neurons at endogenous CerS1

exp_upr_markers_in_patient_neurons

Differentiate neurons from CERS1 patient iPSCs and isogenic controls, and measure UPR branch activation, C18-ceramide, and apoptotic markers over extended culture without any knockdown. If chronic partial CerS1 deficiency in a post-mitotic human neuron does not engage the UPR, the canonical mechanism needs replacing with the sphingolipid homeostasis account rather than supplementing.

Why does CerS1 loss produce cerebellar Purkinje cell degeneration in mice and a cortical-type myoclonic epilepsy with dementia in humans?

KNOWLEDGE GAP OPEN gap_human_and_mouse_regional_patterns_disagree

Attached to

pathophysiology#Neuronal Degeneration pathophysiology#Progressive Myoclonus Epilepsy Syndrome

Both species lose the same enzyme, and in the mouse the loss is complete. Yet the mice are ataxic with Purkinje cell death and the patients have myoclonus, generalized seizures and dementia with variable ataxia. No source available to this entry reports seizures in the mutant mice at all, which means the defining feature of the human disease has no model. Several readings are open: CerS1 expression or the ceramide requirement may differ regionally between species; the human hypomorphic allele may spare cell types a null would kill; or the lipofuscin accumulation, which the mouse shows across many brain regions rather than only the cerebellum, may be the better correlate of the human phenotype than the Purkinje cell death is. Which of these holds determines whether the mouse can be used to test therapy for the human disease.

Proposed experiments

EEG phenotyping and region-resolved lipidomics in Cers1 mutant mice

exp_eeg_and_regional_lipidomics_in_cers1_mutants

Record chronic EEG in flincher and toppler mice to establish whether epileptiform activity is present but unreported, and pair this with region-resolved C18-ceramide measurement across cerebellum, cortex and hippocampus in both species where tissue permits. A mouse with subclinical cortical epileptiform activity would reconcile the two phenotypes; a mouse with none would mean the model cannot serve the epilepsy arm.

Failing to make ceramide (CERS1) and failing to degrade it (ASAH1) both cause progressive myoclonus epilepsy. What does that convergence mean?

KNOWLEDGE GAP OPEN gap_why_ceramide_loss_and_ceramide_excess_converge

Attached to

pathophysiology#Reduced C18-Ceramide

CERS1 disease and SMA-PME are opposite lesions in the same lipid, and they produce overlapping syndromes. The naive reading - that neurons need a particular ceramide abundance and suffer on either side of it - is possible but not obviously right, because the two enzymes act on different pools and different acyl chain lengths, and acid ceramidase failure causes lysosomal storage while ceramide synthase failure does not. An alternative reading is that both diseases converge on flux rather than abundance: what neurons require is turnover through the sphingolipid pathway, and blocking it at either end is equivalent. The founding mouse paper's own caution is relevant here - it states that whether sphingolipid changes in neurodegenerative disease are pathological events or homeostatic responses remains largely unclear, which is exactly the question this convergence poses.

Proposed experiments

Sphingolipid flux versus steady-state abundance in paired CERS1 and ASAH1 models

exp_flux_versus_abundance_in_paired_models

Apply stable-isotope tracing to measure sphingolipid pathway flux, alongside steady-state lipidomics, in neurons from CERS1-deficient and ASAH1-deficient models side by side. If the two share a flux signature while their abundance profiles diverge, flux is the neuronal requirement and the convergence is explained; if abundance of a shared species is what they share, the naive reading holds.

⚙

Pathophysiology

6

CERS1 Loss of Function

The initiating lesion. CerS1 is a transmembrane protein of the endoplasmic reticulum that catalyzes the biosynthesis of C18-ceramides. Of the six mammalian ceramide synthases, CerS1 is the neuronal one, and its acyl-chain specificity is what makes the disorder neurological rather than systemic: the enzyme is not making ceramide in general, it is making one chain length that neurons depend on.

CERS1 hgnc:14253

sphingosine N-acyltransferase activity GO:0050291 ↓ DECREASED

endoplasmic reticulum membrane GO:0005789

Downstream

Reduced C18-Ceramide Loss of catalytic activity lowers the product.

Show evidence (1 reference)

PMID:24782409 SUPPORT Human Clinical

"CerS1, a transmembrane protein of the endoplasmic reticulum (ER), catalyzes the biosynthesis of C18-ceramides"

The enzyme's localization and its specific product, both of which the downstream mechanism depends on.

Reduced C18-Ceramide

The measured biochemical consequence. The patient variant decreases C18-ceramide levels, and in the mouse the equivalent lesion abolishes CerS1 catalytic activity outright, reducing sphingolipid biosynthesis across the brain and shifting steady-state levels of sphingolipids and sphingoid bases. Ceramide is not only a membrane building block but a signalling lipid, which is why a change in its abundance has consequences beyond structure.

ceramide biosynthetic process GO:0046513 ↓ DECREASED

Animal models

Lass1/Cers1 flincher and toppler mice Mouse recapitulates Complete loss of CerS1 activity with brain-wide sphingolipid consequences.

Downstream

Endoplasmic Reticulum Stress Response Established by knockdown rather than in patient neurons - see the discussion.

Lipofuscin Accumulation with Ubiquitylated Proteins A mouse finding whose route from the lipid defect is not established.

Show evidence (2 references)

PMID:24782409 SUPPORT Human Clinical

"We demonstrated that the mutation decreases C18-ceramide levels"

The direct biochemical measurement in the human variant.

PMID:21625621 SUPPORT Model Organism

"Both fln and to mutations caused complete loss of CerS1 catalytic activity, which resulted in a reduction in sphingolipid biosynthesis in the brain and dramatic changes in steady-state levels of sphingolipids and sphingoid bases"

The mouse equivalent, showing the brain-wide lipid consequence that the human study could not measure in tissue.

Endoplasmic Reticulum Stress Response

Downregulating CerS1 in a neuroblastoma cell line triggers an ER stress response and induces proapoptotic pathways. That CerS1 sits in the ER membrane makes this the expected place for the consequence to appear. The node is curated from a knockdown in a tumour-derived cell line, which is the entry's principal evidential limitation and is recorded as its own discussion rather than glossed.

response to endoplasmic reticulum stress GO:0034976 ↑ INCREASED apoptotic process GO:0006915 ↑ INCREASED

Downstream

Neuronal Degeneration Proapoptotic signalling in a cell line is not the same as neuronal loss in a brain, and no source available to this entry bridges them in human tissue.

Show evidence (1 reference)

PMID:24782409 SUPPORT In Vitro

"we showed that downregulation of CerS1 in a neuroblastoma cell line triggers ER stress response and induces proapoptotic pathways"

The cellular mechanism, with the model system named in the quote itself so the limitation travels with the claim.

Lipofuscin Accumulation with Ubiquitylated Proteins

In CerS1-deficient mice, lipofuscin accumulates together with ubiquitylated proteins across many brain regions - a storage-disease-like picture in what is otherwise a biosynthetic defect. This matters for the differential: lipofuscin accumulation is the defining feature of the neuronal ceroid lipofuscinoses, several of which also present as progressive myoclonus epilepsy. Whether the same accumulation occurs in human CERS1 disease is not established.

neuron CL:0000540

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"In addition to Purkinje cell death, deficiency of CerS1 function also induced accumulation of lipofuscin with ubiquitylated proteins in many brain regions"

The storage phenotype in the mouse, and its distribution beyond the cerebellum.

Neuronal Degeneration

Progressive neuronal loss. In the mouse the degeneration is strikingly regional - the two independent Lass1 mutants both present as cerebellar ataxia with Purkinje cell degeneration - whereas the human disorder leads with myoclonic epilepsy and dementia and ataxia is variable. The entry curates the human and mouse regional patterns as different, because they are, and does not smooth one into the other.

Purkinje cell CL:0000121 neuron CL:0000540

Animal models

Lass1/Cers1 flincher and toppler mice Mouse partially recapitulates Neurodegeneration is reproduced; its distribution and the epilepsy are not.

Downstream

Progressive Myoclonus Epilepsy Syndrome No source available to this entry measures excitability, synaptic function or network synchrony in CerS1-deficient neurons, so the step from degeneration to seizures is inferential.

Show evidence (2 references)

PMID:21625621 SUPPORT Model Organism

"We identified two mouse strains, flincher (fln) and toppler (to), with spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell degeneration"

The neurodegenerative phenotype in two independently arising mutants, which is what makes the mouse evidence more than a single-allele observation.

PMID:24782409 SUPPORT Human Clinical

"This study demonstrates that impairment of ceramide biosynthesis underlies neurodegeneration in humans"

The study's own conclusion, and the claim that gives this disorder its significance beyond its rarity.

Progressive Myoclonus Epilepsy Syndrome

The clinical endpoint: action myoclonus, generalized tonic-clonic seizures and progressive cognitive decline, with onset between 6 and 16 years. Conformance attaches at the module's Recurrent Unprovoked Seizures node rather than at the excitation-inhibition or hyperexcitability nodes, because nothing in the available evidence measures excitability in this disorder - the mechanism is established as neurodegenerative, and the epileptic consequence is observed rather than explained.

Show evidence (1 reference)

PMID:27618929 SUPPORT Human Clinical

"an unusual, severe form of progressive myoclonus epilepsy characterized by myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive impairment, with probable autosomal recessive inheritance. Disease onset was between 6 and 16 years of age"

The clinical syndrome and its age range, in the one described family.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Myoclonus Neurological HP:0001336

Show evidence (1 reference)

PMID:27618929 SUPPORT Human Clinical

"characterized by myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive impairment"

Names myoclonus as a defining feature. The reported cohort is a single family, so no frequency band is asserted anywhere in this entry.

Generalized Tonic-Clonic Seizures Neurological HP:0002069

Show evidence (1 reference)

PMID:27618929 SUPPORT Human Clinical

"myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive impairment"

Names the seizure type in the reported family.

Progressive Cognitive Decline Neurological HP:0001268

Show evidence (2 references)

PMID:24782409 SUPPORT Human Clinical

"4 siblings affected by a progressive disorder with myoclonic epilepsy and dementia"

Establishes the progressive cognitive component alongside the epilepsy.

PMID:27618929 SUPPORT Human Clinical

"moderate to severe cognitive impairment"

Records the severity range as reported.

Ataxia Neurological HP:0001251

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell degeneration"

Curated PARTIAL and MODEL_ORGANISM deliberately. This is mouse evidence supporting a human phenotype, which the evidence policy warns against relying on alone. The human case report describing prominent ataxia (PMID:30800706) caches as metadata without an abstract, so no quotable human sentence is available to pair with it.

🧬

Genetic Associations

1

CERS1 (Biallelic CERS1 variants cause progressive myoclonic epilepsy type 8. The founding variant is a homozygous nonsynonymous change identified in four affected siblings, shown to decrease C18-ceramide levels. CERS1 is one of six mammalian ceramide synthases, each with a distinct fatty acyl-CoA chain-length preference; CerS1 is the neuronal enzyme and makes C18-ceramide, which is what confines the disease to the nervous system.)

Gene: CERS1 hgnc:14253 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:24782409 SUPPORT Human Clinical

"We identified a homozygous nonsynonymous mutation in CERS1, the gene encoding ceramide synthase 1"

The gene-disease assertion.

PMID:21625621 SUPPORT Model Organism

"Positional cloning demonstrated that these mutations reside in the Lass1 gene. Lass1 encodes (dihydro)ceramide synthase 1 (CerS1), which is highly expressed in neurons"

Independent genetic evidence from the mouse, and the neuronal expression pattern that explains the tissue restriction. Lass1 is the former name of the gene now called Cers1.

💊

Medical Actions

2

Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867

Management is symptomatic. No disease-modifying therapy exists and no agent has efficacy evidence specific to CERS1-related disease. Treatment follows general progressive myoclonus epilepsy practice: valproic acid is the usual first-line antiseizure medication, while sodium channel blockers and GABAergic drugs are conventionally avoided because they can exacerbate myoclonus. Both claims are curated from evidence about the progressive myoclonus epilepsy group; no source states either for this disorder specifically.

Show evidence (2 references)

PMID:41817056 SUPPORT Human Clinical

"Valproic acid is often the first-line ASM in treating PME due to its high effectiveness on myoclonus, seizures, and photosensitivity, except in MERRF."

Names the first-line agent and the reason for choosing it. Curated PARTIAL because the recommendation is made for the progressive myoclonus epilepsy group as a whole; no study has tested valproate in CERS1-related disease.

PMID:41817056 SUPPORT Human Clinical

"Sodium channel blockers (phenytoin, carbamazepine, and oxcarbazepine) and GABAergic drugs (gabapentin, pregabalin, and vigabatrin) are to be avoided, as these drugs may exacerbate myoclonus and myoclonic seizures."

Supports the agents-to-avoid caveat asserted in this entry's description, named to the individual drug and with the mechanism of harm. Curated PARTIAL for the same reason: it is a group-level recommendation, not a CERS1-specific one.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Autosomal recessive counseling with a 25 percent recurrence risk per pregnancy. Relevant in practice because the reported families are consanguineous, where carrier frequency within the kindred is elevated.

Show evidence (1 reference)

PMID:27618929 SUPPORT Human Clinical

"with probable autosomal recessive inheritance"

The inheritance mode on which the recurrence risk depends.

🔬

Diagnosis

1

Molecular Genetic Testing

The diagnosis is molecular. Progressive myoclonus epilepsy is a syndromic diagnosis with many genetic causes, and the yield of genetic testing across the group is now high, so CERS1 is reached through a panel or exome rather than suspected on clinical grounds - nothing in the phenotype points to ceramide synthase specifically.

Whole Exome Sequencing NCIT:C101295

Show evidence (2 references)

PMID:41817056 SUPPORT Human Clinical

"The clinical features and genetic underpinnings of PME are diverse, with approximately 80% of individuals now able to receive a molecular diagnosis"

Establishes that molecular diagnosis is achievable for most patients with this syndrome, which is what makes gene-agnostic testing the route to a CERS1 diagnosis.

PMID:33798445 SUPPORT Human Clinical

"Progressive myoclonus epilepsies (PMEs) comprise a group of clinically and genetically heterogeneous rare diseases. Over 70% of PME cases can now be molecularly solved"

The genetic heterogeneity that makes broad testing necessary, with a second yield estimate from an independent review.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

Extremely rare even among the progressive myoclonus epilepsies. As of the cited review the disorder had been reported in a single family of Algerian origin; a further isolated case has since been described, and a systematic exome study of 78 unsolved PME-affected individuals returned CERS1 in one further family. Progressive myoclonus epilepsies as a group are rare, and CERS1 is among the rarest causes within them.

Show evidence (2 references)

PMID:27618929 SUPPORT Human Clinical

"Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis is an extremely rare condition, so far reported in a single family of Algerian origin"

The reported case count at the time of this review, and the source's own characterization of the rarity.

PMID:33798445 SUPPORT Human Clinical

"in five families, we identified variants in established PME genes; three with intronic or copy-number changes (CLN6, GBA, NEU1) and two very rare causes (ASAH1, CERS1)"

An additional CERS1-solved family, found by systematically exome-sequencing 78 unsolved PME cases. This is the quantitative anchor for the rarity claim: across a cohort assembled specifically to find residual PME causes, CERS1 accounted for one family, and the authors class it among the very rare causes.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Progressive Myoclonic Epilepsy Type 8:

Other progressive myoclonus epilepsies

Overlapping Features Unverricht-Lundborg disease, Lafora disease, the neuronal ceroid lipofuscinoses, MERRF and sialidosis all present with the same triad of myoclonus, seizures and cognitive decline. CERS1 is not distinguishable from them clinically, and the group is genetically heterogeneous enough that testing is gene-agnostic.

Distinguishing Features

Distinguished by molecular genetic testing rather than by clinical features; over 70 percent of progressive myoclonus epilepsy cases are now molecularly solved.
Age at onset between 6 and 16 years overlaps with Unverricht-Lundborg and Lafora disease and does not discriminate.

Show evidence (1 reference)

PMID:33798445 SUPPORT Human Clinical

"Progressive myoclonus epilepsies (PMEs) comprise a group of clinically and genetically heterogeneous rare diseases"

Establishes the clinical and genetic heterogeneity that makes this a molecular rather than a clinical differential.

🐁

Animal Models

1

Lass1/Cers1 flincher and toppler mice

Two independently arising spontaneous mouse mutants mapping to the same gene, both abolishing CerS1 catalytic activity. Their independence is what makes them evidentially strong: two separate mutational events producing the same phenotype in the same gene is much harder to attribute to background than a single engineered allele would be.

Species

Mouse

Genotype

spontaneous recessive Lass1 (Cers1) mutations, flincher (fln) and toppler (to)

Publication

PMID:21625621

Pathograph links

Reduced C18-Ceramide recapitulates fidelity: high Complete loss of CerS1 activity with brain-wide sphingolipid consequences.

Limitations: The mouse alleles abolish catalytic activity completely, whereas the human founding variant is a nonsynonymous change that decreases C18-ceramide rather than eliminating the enzyme. The model therefore tests the null state, not the patient allele, and may overstate severity.

Readouts

Brain sphingolipid and sphingoid base levels

Direction: ALTERED

Interpretation: Sphingolipid biosynthesis falls and steady-state sphingolipid and sphingoid base levels shift substantially. ALTERED rather than DECREASED because the source reports a change in the profile, not a uniform fall.

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"a reduction in sphingolipid biosynthesis in the brain and dramatic changes in steady-state levels of sphingolipids and sphingoid bases"

The lipidomic measurement behind this readout.

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"Both fln and to mutations caused complete loss of CerS1 catalytic activity"

Establishes that both alleles are functional nulls, which is what the model tests.

Neuronal Degeneration partially recapitulates fidelity: moderate Neurodegeneration is reproduced; its distribution and the epilepsy are not.

Limitations: The regional pattern does not match. The mice present with cerebellar ataxia and Purkinje cell degeneration, while the human disorder leads with myoclonic epilepsy and dementia, with ataxia variable. No source reports seizures in these mice, so the defining feature of the human disease is not demonstrated in the model at all.

Readouts

Purkinje cell survival

Direction: DECREASED

Interpretation: Purkinje cell death is the dominant neurodegenerative finding in both mutants.

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell degeneration"

The neuropathological readout.

Lipofuscin and ubiquitylated protein accumulation

Direction: INCREASED

Interpretation: A storage phenotype accompanying the cell death, and distributed more widely than the cell death itself.

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"deficiency of CerS1 function also induced accumulation of lipofuscin with ubiquitylated proteins in many brain regions"

The storage measurement behind this readout.

Show evidence (1 reference)

PMID:21625621 SUPPORT Model Organism

"We identified two mouse strains, flincher (fln) and toppler (to), with spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell degeneration"

Curated PARTIAL for this node because the model reproduces neurodegeneration while its regional distribution differs from the human disease and the epilepsy is absent.

{ }

Source YAML

click to show

name: Progressive Myoclonic Epilepsy Type 8
creation_date: "2026-08-20T19:00:00Z"
category: Mendelian
synonyms:
- EPM8
- Progressive myoclonus epilepsy type 8
- CERS1-related progressive myoclonic epilepsy
- Progressive myoclonus epilepsy due to impaired ceramide synthesis
description: >-
  Progressive myoclonic epilepsy type 8 is an autosomal recessive progressive myoclonus
  epilepsy caused by biallelic variants in CERS1, which encodes ceramide synthase 1. CerS1
  is an endoplasmic reticulum transmembrane enzyme that makes C18-ceramide, and it is the
  ceramide synthase of neurons. Losing it lowers C18-ceramide, triggers an ER stress
  response and induces proapoptotic signalling, producing myoclonus, generalized
  tonic-clonic seizures and progressive cognitive decline from school age. It is the
  disorder that established impaired ceramide biosynthesis as a cause of human
  neurodegeneration, and it remains among the rarest of the progressive myoclonus
  epilepsies - the human evidence rests on very few families, and much of the mechanistic
  weight is carried by two spontaneous mouse mutants.
disease_term:
  preferred_term: progressive myoclonic epilepsy type 8
  term:
    id: MONDO:0014545
    label: progressive myoclonic epilepsy type 8
parents:
- Epilepsy
- Neurological Disease
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Biallelic CERS1 variants. The founding report described four affected siblings
    homozygous for a nonsynonymous variant in a consanguineous family.
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a homozygous nonsynonymous mutation in CERS1, the gene encoding
      ceramide synthase 1, in 4 siblings affected by a progressive disorder with myoclonic
      epilepsy and dementia"
    explanation: >-
      Establishes the recessive architecture and the size of the founding pedigree.

pathophysiology:

- name: CERS1 Loss of Function
  biological_scale: MOLECULAR
  description: >-
    The initiating lesion. CerS1 is a transmembrane protein of the endoplasmic reticulum
    that catalyzes the biosynthesis of C18-ceramides. Of the six mammalian ceramide
    synthases, CerS1 is the neuronal one, and its acyl-chain specificity is what makes the
    disorder neurological rather than systemic: the enzyme is not making ceramide in general,
    it is making one chain length that neurons depend on.
  genes:
  - preferred_term: CERS1
    term:
      id: hgnc:14253
      label: CERS1
  molecular_functions:
  - preferred_term: sphingosine N-acyltransferase activity
    term:
      id: GO:0050291
      label: sphingosine N-acyltransferase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: endoplasmic reticulum membrane
    term:
      id: GO:0005789
      label: endoplasmic reticulum membrane
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CerS1, a transmembrane protein of the endoplasmic reticulum (ER), catalyzes
      the biosynthesis of C18-ceramides"
    explanation: >-
      The enzyme's localization and its specific product, both of which the downstream
      mechanism depends on.
  downstream:
  - target: Reduced C18-Ceramide
    causal_link_type: DIRECT
    description: >-
      Loss of catalytic activity lowers the product.

- name: Reduced C18-Ceramide
  biological_scale: MOLECULAR
  description: >-
    The measured biochemical consequence. The patient variant decreases C18-ceramide levels,
    and in the mouse the equivalent lesion abolishes CerS1 catalytic activity outright,
    reducing sphingolipid biosynthesis across the brain and shifting steady-state levels of
    sphingolipids and sphingoid bases. Ceramide is not only a membrane building block but a
    signalling lipid, which is why a change in its abundance has consequences beyond
    structure.
  chemical_entities:
  - preferred_term: ceramide
    term:
      id: CHEBI:17761
      label: ceramide
    modifier: DECREASED
  biological_processes:
  - preferred_term: ceramide biosynthetic process
    term:
      id: GO:0046513
      label: ceramide biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We demonstrated that the mutation decreases C18-ceramide levels"
    explanation: >-
      The direct biochemical measurement in the human variant.
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Both fln and to mutations caused complete loss of CerS1 catalytic activity,
      which resulted in a reduction in sphingolipid biosynthesis in the brain and dramatic
      changes in steady-state levels of sphingolipids and sphingoid bases"
    explanation: >-
      The mouse equivalent, showing the brain-wide lipid consequence that the human study
      could not measure in tissue.
  downstream:
  - target: Endoplasmic Reticulum Stress Response
    causal_link_type: DIRECT
    description: >-
      Established by knockdown rather than in patient neurons - see the discussion.
  - target: Lipofuscin Accumulation with Ubiquitylated Proteins
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A mouse finding whose route from the lipid defect is not established.

- name: Endoplasmic Reticulum Stress Response
  biological_scale: CELLULAR
  description: >-
    Downregulating CerS1 in a neuroblastoma cell line triggers an ER stress response and
    induces proapoptotic pathways. That CerS1 sits in the ER membrane makes this the
    expected place for the consequence to appear. The node is curated from a knockdown in a
    tumour-derived cell line, which is the entry's principal evidential limitation and is
    recorded as its own discussion rather than glossed.
  biological_processes:
  - preferred_term: response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we showed that downregulation of CerS1 in a neuroblastoma cell line triggers
      ER stress response and induces proapoptotic pathways"
    explanation: >-
      The cellular mechanism, with the model system named in the quote itself so the
      limitation travels with the claim.
  downstream:
  - target: Neuronal Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Proapoptotic signalling in a cell line is not the same as neuronal loss in a brain,
      and no source available to this entry bridges them in human tissue.

- name: Lipofuscin Accumulation with Ubiquitylated Proteins
  biological_scale: CELLULAR
  description: >-
    In CerS1-deficient mice, lipofuscin accumulates together with ubiquitylated proteins
    across many brain regions - a storage-disease-like picture in what is otherwise a
    biosynthetic defect. This matters for the differential: lipofuscin accumulation is the
    defining feature of the neuronal ceroid lipofuscinoses, several of which also present as
    progressive myoclonus epilepsy. Whether the same accumulation occurs in human CERS1
    disease is not established.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In addition to Purkinje cell death, deficiency of CerS1 function also induced
      accumulation of lipofuscin with ubiquitylated proteins in many brain regions"
    explanation: >-
      The storage phenotype in the mouse, and its distribution beyond the cerebellum.

- name: Neuronal Degeneration
  biological_scale: TISSUE
  description: >-
    Progressive neuronal loss. In the mouse the degeneration is strikingly regional - the
    two independent Lass1 mutants both present as cerebellar ataxia with Purkinje cell
    degeneration - whereas the human disorder leads with myoclonic epilepsy and dementia and
    ataxia is variable. The entry curates the human and mouse regional patterns as
    different, because they are, and does not smooth one into the other.
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We identified two mouse strains, flincher (fln) and toppler (to), with
      spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell
      degeneration"
    explanation: >-
      The neurodegenerative phenotype in two independently arising mutants, which is what
      makes the mouse evidence more than a single-allele observation.
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study demonstrates that impairment of ceramide biosynthesis underlies
      neurodegeneration in humans"
    explanation: >-
      The study's own conclusion, and the claim that gives this disorder its significance
      beyond its rarity.
  downstream:
  - target: Progressive Myoclonus Epilepsy Syndrome
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      No source available to this entry measures excitability, synaptic function or network
      synchrony in CerS1-deficient neurons, so the step from degeneration to seizures is
      inferential.

- name: Progressive Myoclonus Epilepsy Syndrome
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  description: >-
    The clinical endpoint: action myoclonus, generalized tonic-clonic seizures and
    progressive cognitive decline, with onset between 6 and 16 years. Conformance attaches
    at the module's Recurrent Unprovoked Seizures node rather than at the
    excitation-inhibition or hyperexcitability nodes, because nothing in the available
    evidence measures excitability in this disorder - the mechanism is established as
    neurodegenerative, and the epileptic consequence is observed rather than explained.
  evidence:
  - reference: PMID:27618929
    reference_title: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an unusual, severe form of progressive myoclonus epilepsy characterized by
      myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive
      impairment, with probable autosomal recessive inheritance. Disease onset was between 6
      and 16 years of age"
    explanation: >-
      The clinical syndrome and its age range, in the one described family.

mechanistic_hypotheses:
- hypothesis_group_id: er_stress_apoptosis_model
  status: CANONICAL
  description: >-
    Loss of C18-ceramide destabilizes ER homeostasis in neurons, the unfolded protein
    response is engaged, and sustained ER stress drives apoptotic neuronal loss. This is the
    account the founding study advanced and it fits the enzyme's ER localization. Its
    evidential base is a knockdown in a neuroblastoma line rather than patient or model
    neurons.
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "downregulation of CerS1 in a neuroblastoma cell line triggers ER stress
      response and induces proapoptotic pathways"
    explanation: >-
      The experimental basis for the model.

- hypothesis_group_id: sphingolipid_membrane_homeostasis_model
  status: ALTERNATIVE
  description: >-
    The primary defect is a broader failure of neuronal sphingolipid homeostasis rather than
    an ER stress response specifically: brain sphingolipid biosynthesis falls and
    steady-state sphingolipid and sphingoid base levels shift dramatically, and it is that
    altered membrane and signalling lipid composition - evidenced by the lipofuscin and
    ubiquitylated protein accumulation - that degrades neurons over time. The mouse data
    speak more directly to this account than to the ER stress one, since they measure
    brain lipids and show a storage phenotype rather than showing an unfolded protein
    response. The two are not exclusive and may be sequential.
  evidence:
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "a reduction in sphingolipid biosynthesis in the brain and dramatic changes in
      steady-state levels of sphingolipids and sphingoid bases"
    explanation: >-
      The brain-wide lipid disturbance this account is built on.
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "it remains largely unclear whether sphingolipid changes in these diseases are
      pathological events or homeostatic responses"
    explanation: >-
      Curated PARTIAL, and quoted deliberately against the hypothesis it belongs to: the
      same paper states that the causal direction of sphingolipid changes in
      neurodegeneration is unresolved in general.

phenotypes:

- category: Neurological
  name: Myoclonus
  description: >-
    Progressively worsening myoclonus, the defining feature of the progressive myoclonus
    epilepsy syndrome.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:27618929
    reference_title: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by myoclonus, generalized tonic-clonic seizures and moderate to
      severe cognitive impairment"
    explanation: >-
      Names myoclonus as a defining feature. The reported cohort is a single family, so no
      frequency band is asserted anywhere in this entry.

- category: Neurological
  name: Generalized Tonic-Clonic Seizures
  description: >-
    Generalized tonic-clonic seizures accompanying the myoclonus.
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: PMID:27618929
    reference_title: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive
      impairment"
    explanation: >-
      Names the seizure type in the reported family.

- category: Neurological
  name: Progressive Cognitive Decline
  description: >-
    Moderate to severe cognitive impairment that worsens over time. The founding report
    described the affected siblings as having myoclonic epilepsy and dementia, which is the
    combination that places this disorder in the progressive myoclonus epilepsy group rather
    than among the static epilepsies.
  phenotype_term:
    preferred_term: Mental deterioration
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "4 siblings affected by a progressive disorder with myoclonic epilepsy and
      dementia"
    explanation: >-
      Establishes the progressive cognitive component alongside the epilepsy.
  - reference: PMID:27618929
    reference_title: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "moderate to severe cognitive impairment"
    explanation: >-
      Records the severity range as reported.

- category: Neurological
  name: Ataxia
  description: >-
    Ataxia is variable in the human disorder but is the dominant feature of the mouse model,
    where both independent mutants present with cerebellar ataxia. One reported human case
    was described as having prominent ataxia, which is why it is curated - but the
    human-mouse difference in prominence is real and is recorded in the discussion rather
    than averaged away.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell
      degeneration"
    explanation: >-
      Curated PARTIAL and MODEL_ORGANISM deliberately. This is mouse evidence supporting a
      human phenotype, which the evidence policy warns against relying on alone. The human
      case report describing prominent ataxia (PMID:30800706) caches as metadata without an
      abstract, so no quotable human sentence is available to pair with it.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Extremely rare even among the progressive myoclonus epilepsies. As of the cited review
    the disorder had been reported in a single family of Algerian origin; a further isolated
    case has since been described, and a systematic exome study of 78 unsolved PME-affected
    individuals returned CERS1 in one further family. Progressive myoclonus epilepsies as a
    group are rare, and CERS1 is among the rarest causes within them.
  evidence:
  - reference: PMID:27618929
    reference_title: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide
      synthesis is an extremely rare condition, so far reported in a single family of
      Algerian origin"
    explanation: >-
      The reported case count at the time of this review, and the source's own
      characterization of the rarity.
  - reference: PMID:33798445
    reference_title: "Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in five families, we identified variants in established PME genes; three with
      intronic or copy-number changes (CLN6, GBA, NEU1) and two very rare causes (ASAH1,
      CERS1)"
    explanation: >-
      An additional CERS1-solved family, found by systematically exome-sequencing 78 unsolved
      PME cases. This is the quantitative anchor for the rarity claim: across a cohort
      assembled specifically to find residual PME causes, CERS1 accounted for one family, and
      the authors class it among the very rare causes.

genetic:
- name: CERS1
  gene_term:
    preferred_term: CERS1
    term:
      id: hgnc:14253
      label: CERS1
  relationship_type: CAUSATIVE
  association: >-
    Biallelic CERS1 variants cause progressive myoclonic epilepsy type 8. The founding
    variant is a homozygous nonsynonymous change identified in four affected siblings, shown
    to decrease C18-ceramide levels. CERS1 is one of six mammalian ceramide synthases, each
    with a distinct fatty acyl-CoA chain-length preference; CerS1 is the neuronal enzyme and
    makes C18-ceramide, which is what confines the disease to the nervous system.
  evidence:
  - reference: PMID:24782409
    reference_title: "Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a homozygous nonsynonymous mutation in CERS1, the gene encoding
      ceramide synthase 1"
    explanation: >-
      The gene-disease assertion.
  - reference: PMID:21625621
    reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Positional cloning demonstrated that these mutations reside in the Lass1 gene.
      Lass1 encodes (dihydro)ceramide synthase 1 (CerS1), which is highly expressed in
      neurons"
    explanation: >-
      Independent genetic evidence from the mouse, and the neuronal expression pattern that
      explains the tissue restriction. Lass1 is the former name of the gene now called Cers1.
  notes: >-
    The gene has been known under two names and both appear in the literature cited here.
    The mouse study calls it Lass1, for longevity assurance homolog 1; the human study calls
    it CERS1. They are the same gene, and a curator meeting the older name in a search
    should not treat it as a separate locus. The HGNC record carries LASS1 as a previous
    symbol.

diagnosis:
- name: Molecular Genetic Testing
  description: >-
    The diagnosis is molecular. Progressive myoclonus epilepsy is a syndromic diagnosis with
    many genetic causes, and the yield of genetic testing across the group is now high, so
    CERS1 is reached through a panel or exome rather than suspected on clinical grounds -
    nothing in the phenotype points to ceramide synthase specifically.
  diagnosis_term:
    preferred_term: Whole Exome Sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  evidence:
  - reference: PMID:41817056
    reference_title: "Progressive Myoclonic Epilepsies - A Pragmatic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical features and genetic underpinnings of PME are diverse, with
      approximately 80% of individuals now able to receive a molecular diagnosis"
    explanation: >-
      Establishes that molecular diagnosis is achievable for most patients with this
      syndrome, which is what makes gene-agnostic testing the route to a CERS1 diagnosis.
  - reference: PMID:33798445
    reference_title: "Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive myoclonus epilepsies (PMEs) comprise a group of clinically and
      genetically heterogeneous rare diseases. Over 70% of PME cases can now be molecularly
      solved"
    explanation: >-
      The genetic heterogeneity that makes broad testing necessary, with a second yield
      estimate from an independent review.

treatments:
- name: Antiseizure Medication
  description: >-
    Management is symptomatic. No disease-modifying therapy exists and no agent has efficacy
    evidence specific to CERS1-related disease. Treatment follows general progressive
    myoclonus epilepsy practice: valproic acid is the usual first-line antiseizure medication,
    while sodium channel blockers and GABAergic drugs are conventionally avoided because they
    can exacerbate myoclonus. Both claims are curated from evidence about the progressive
    myoclonus epilepsy group; no source states either for this disorder specifically.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
  evidence:
  - reference: PMID:41817056
    reference_title: "Progressive Myoclonic Epilepsies - A Pragmatic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Valproic acid is often the first-line ASM in treating PME due to its high
      effectiveness on myoclonus, seizures, and photosensitivity, except in MERRF."
    explanation: >-
      Names the first-line agent and the reason for choosing it. Curated PARTIAL because the
      recommendation is made for the progressive myoclonus epilepsy group as a whole; no
      study has tested valproate in CERS1-related disease.
  - reference: PMID:41817056
    reference_title: "Progressive Myoclonic Epilepsies - A Pragmatic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sodium channel blockers (phenytoin, carbamazepine, and oxcarbazepine) and
      GABAergic drugs (gabapentin, pregabalin, and vigabatrin) are to be avoided, as these
      drugs may exacerbate myoclonus and myoclonic seizures."
    explanation: >-
      Supports the agents-to-avoid caveat asserted in this entry's description, named to the
      individual drug and with the mechanism of harm. Curated PARTIAL for the same reason: it
      is a group-level recommendation, not a CERS1-specific one.
  notes: >-
    Everything curated here is progressive myoclonus epilepsy practice applied to a disorder
    in which no drug has actually been studied - the reported literature is essentially one
    family plus isolated cases. The mechanism suggests ceramide supplementation or ER stress
    modulation as rational targets, but neither has been tested and neither is curated as a
    treatment.

- name: Genetic Counseling
  description: >-
    Autosomal recessive counseling with a 25 percent recurrence risk per pregnancy. Relevant
    in practice because the reported families are consanguineous, where carrier frequency
    within the kindred is elevated.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:27618929
    reference_title: "Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with probable autosomal recessive inheritance"
    explanation: >-
      The inheritance mode on which the recurrence risk depends.

animal_models:
- name: Lass1/Cers1 flincher and toppler mice
  species: Mouse
  genotype: spontaneous recessive Lass1 (Cers1) mutations, flincher (fln) and toppler (to)
  publication: PMID:21625621
  description: >-
    Two independently arising spontaneous mouse mutants mapping to the same gene, both
    abolishing CerS1 catalytic activity. Their independence is what makes them evidentially
    strong: two separate mutational events producing the same phenotype in the same gene is
    much harder to attribute to background than a single engineered allele would be.
  modeled_mechanisms:
  - target: Reduced C18-Ceramide
    relationship: RECAPITULATES
    fidelity: HIGH
    limitations: >-
      The mouse alleles abolish catalytic activity completely, whereas the human founding
      variant is a nonsynonymous change that decreases C18-ceramide rather than eliminating
      the enzyme. The model therefore tests the null state, not the patient allele, and may
      overstate severity.
    description: >-
      Complete loss of CerS1 activity with brain-wide sphingolipid consequences.
    readouts:
    - name: Brain sphingolipid and sphingoid base levels
      target: Reduced C18-Ceramide
      direction: ALTERED
      interpretation: >-
        Sphingolipid biosynthesis falls and steady-state sphingolipid and sphingoid base
        levels shift substantially. ALTERED rather than DECREASED because the source reports
        a change in the profile, not a uniform fall.
      evidence:
      - reference: PMID:21625621
        reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "a reduction in sphingolipid biosynthesis in the brain and dramatic changes
          in steady-state levels of sphingolipids and sphingoid bases"
        explanation: >-
          The lipidomic measurement behind this readout.
    evidence:
    - reference: PMID:21625621
      reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Both fln and to mutations caused complete loss of CerS1 catalytic activity"
      explanation: >-
        Establishes that both alleles are functional nulls, which is what the model tests.
  - target: Neuronal Degeneration
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    limitations: >-
      The regional pattern does not match. The mice present with cerebellar ataxia and
      Purkinje cell degeneration, while the human disorder leads with myoclonic epilepsy and
      dementia, with ataxia variable. No source reports seizures in these mice, so the
      defining feature of the human disease is not demonstrated in the model at all.
    description: >-
      Neurodegeneration is reproduced; its distribution and the epilepsy are not.
    readouts:
    - name: Purkinje cell survival
      target: Neuronal Degeneration
      direction: DECREASED
      interpretation: >-
        Purkinje cell death is the dominant neurodegenerative finding in both mutants.
      evidence:
      - reference: PMID:21625621
        reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "spontaneous recessive mutations that cause cerebellar ataxia and Purkinje
          cell degeneration"
        explanation: >-
          The neuropathological readout.
    - name: Lipofuscin and ubiquitylated protein accumulation
      target: Neuronal Degeneration
      direction: INCREASED
      interpretation: >-
        A storage phenotype accompanying the cell death, and distributed more widely than
        the cell death itself.
      evidence:
      - reference: PMID:21625621
        reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "deficiency of CerS1 function also induced accumulation of lipofuscin with
          ubiquitylated proteins in many brain regions"
        explanation: >-
          The storage measurement behind this readout.
    evidence:
    - reference: PMID:21625621
      reference_title: "A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We identified two mouse strains, flincher (fln) and toppler (to), with
        spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell
        degeneration"
      explanation: >-
        Curated PARTIAL for this node because the model reproduces neurodegeneration while
        its regional distribution differs from the human disease and the epilepsy is absent.

differential_diagnoses:
- name: Other progressive myoclonus epilepsies
  description: >-
    Unverricht-Lundborg disease, Lafora disease, the neuronal ceroid lipofuscinoses, MERRF
    and sialidosis all present with the same triad of myoclonus, seizures and cognitive
    decline. CERS1 is not distinguishable from them clinically, and the group is genetically
    heterogeneous enough that testing is gene-agnostic.
  distinguishing_features:
  - >-
    Distinguished by molecular genetic testing rather than by clinical features; over 70
    percent of progressive myoclonus epilepsy cases are now molecularly solved.
  - >-
    Age at onset between 6 and 16 years overlaps with Unverricht-Lundborg and Lafora disease
    and does not discriminate.
  evidence:
  - reference: PMID:33798445
    reference_title: "Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive myoclonus epilepsies (PMEs) comprise a group of clinically and
      genetically heterogeneous rare diseases"
    explanation: >-
      Establishes the clinical and genetic heterogeneity that makes this a molecular rather
      than a clinical differential.

- name: SMA-PME (ASAH1-related)
  description: >-
    Spinal muscular atrophy with progressive myoclonic epilepsy, caused by ASAH1 variants.
    It is the closest mechanistic neighbour rather than merely another entry on the list:
    ASAH1 encodes acid ceramidase, which degrades ceramide, while CERS1 synthesizes it.
    Two opposite lesions in the same lipid produce overlapping progressive myoclonus
    epilepsy - which is an argument that ceramide homeostasis rather than ceramide abundance
    is what neurons require.
  distinguishing_features:
  - >-
    Lower motor neuron disease with muscle weakness and denervation is a defining feature of
    SMA-PME and is not described in CERS1-related disease.
  evidence:
  - reference: PMID:27647482
    reference_title: "Spinal muscular atrophy associated with progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A rare syndrome characterized by lower motor neuron disease associated with
      progressive myoclonic epilepsy, referred to as \"spinal muscular atrophy associated
      with progressive myoclonic epilepsy\" (SMA-PME)"
    explanation: >-
      Defines the syndrome and names the lower motor neuron involvement that distinguishes
      it.

discussions:

- discussion_id: mismatch_er_stress_rests_on_a_neuroblastoma_knockdown
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Endoplasmic Reticulum Stress Response
  prompt: >-
    Does ER stress and proapoptotic signalling after CerS1 knockdown in a neuroblastoma line
    report what happens in a CERS1-deficient human neuron?
  rationale: >-
    This is the entry's weakest link and it sits in the middle of the canonical mechanism.
    The claim that loss of CerS1 causes ER stress and apoptosis comes from acute
    downregulation in a tumour-derived cell line. Three gaps separate that from the disease.
    Neuroblastoma cells are proliferating and transformed, with a lipid metabolism unlike a
    post-mitotic neuron's. Acute knockdown is not the same as lifelong reduced activity, and
    an acute drop is far more likely to provoke a stress response than a chronic set-point
    change. And the human variant reduces C18-ceramide rather than abolishing the enzyme,
    while the knockdown removes it. The mouse work, which is the better model, measures
    lipids and storage material but does not report an unfolded protein response - so the ER
    stress account is not independently corroborated.
  proposed_experiments:
  - experiment_id: exp_upr_markers_in_patient_neurons
    name: Unfolded protein response markers in patient-derived neurons at endogenous CerS1
    description: >-
      Differentiate neurons from CERS1 patient iPSCs and isogenic controls, and measure UPR
      branch activation, C18-ceramide, and apoptotic markers over extended culture without
      any knockdown. If chronic partial CerS1 deficiency in a post-mitotic human neuron does
      not engage the UPR, the canonical mechanism needs replacing with the sphingolipid
      homeostasis account rather than supplementing.

- discussion_id: gap_human_and_mouse_regional_patterns_disagree
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Neuronal Degeneration
  - pathophysiology#Progressive Myoclonus Epilepsy Syndrome
  prompt: >-
    Why does CerS1 loss produce cerebellar Purkinje cell degeneration in mice and a
    cortical-type myoclonic epilepsy with dementia in humans?
  rationale: >-
    Both species lose the same enzyme, and in the mouse the loss is complete. Yet the mice
    are ataxic with Purkinje cell death and the patients have myoclonus, generalized seizures
    and dementia with variable ataxia. No source available to this entry reports seizures in
    the mutant mice at all, which means the defining feature of the human disease has no
    model. Several readings are open: CerS1 expression or the ceramide requirement may differ
    regionally between species; the human hypomorphic allele may spare cell types a null
    would kill; or the lipofuscin accumulation, which the mouse shows across many brain
    regions rather than only the cerebellum, may be the better correlate of the human
    phenotype than the Purkinje cell death is. Which of these holds determines whether the
    mouse can be used to test therapy for the human disease.
  proposed_experiments:
  - experiment_id: exp_eeg_and_regional_lipidomics_in_cers1_mutants
    name: EEG phenotyping and region-resolved lipidomics in Cers1 mutant mice
    description: >-
      Record chronic EEG in flincher and toppler mice to establish whether epileptiform
      activity is present but unreported, and pair this with region-resolved C18-ceramide
      measurement across cerebellum, cortex and hippocampus in both species where tissue
      permits. A mouse with subclinical cortical epileptiform activity would reconcile the
      two phenotypes; a mouse with none would mean the model cannot serve the epilepsy arm.

- discussion_id: gap_why_ceramide_loss_and_ceramide_excess_converge
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced C18-Ceramide
  prompt: >-
    Failing to make ceramide (CERS1) and failing to degrade it (ASAH1) both cause progressive
    myoclonus epilepsy. What does that convergence mean?
  rationale: >-
    CERS1 disease and SMA-PME are opposite lesions in the same lipid, and they produce
    overlapping syndromes. The naive reading - that neurons need a particular ceramide
    abundance and suffer on either side of it - is possible but not obviously right, because
    the two enzymes act on different pools and different acyl chain lengths, and acid
    ceramidase failure causes lysosomal storage while ceramide synthase failure does not.
    An alternative reading is that both diseases converge on flux rather than abundance:
    what neurons require is turnover through the sphingolipid pathway, and blocking it at
    either end is equivalent. The founding mouse paper's own caution is relevant here - it
    states that whether sphingolipid changes in neurodegenerative disease are pathological
    events or homeostatic responses remains largely unclear, which is exactly the question
    this convergence poses.
  proposed_experiments:
  - experiment_id: exp_flux_versus_abundance_in_paired_models
    name: Sphingolipid flux versus steady-state abundance in paired CERS1 and ASAH1 models
    description: >-
      Apply stable-isotope tracing to measure sphingolipid pathway flux, alongside
      steady-state lipidomics, in neurons from CERS1-deficient and ASAH1-deficient models
      side by side. If the two share a flux signature while their abundance profiles diverge,
      flux is the neuronal requirement and the convergence is explained; if abundance of a
      shared species is what they share, the naive reading holds.

notes: >-
  Scope and evidence base. This entry curates progressive myoclonic epilepsy type 8, the
  CERS1 disorder. The human literature is genuinely thin - the founding report of four
  affected siblings in one Algerian family, a review restating that family, one further
  family recovered by a systematic exome study of unsolved PME cases, and an isolated later
  case whose record caches as metadata without an abstract, so nothing in it is
  quotable. As a result no frequency bands are asserted anywhere in this entry, and much of
  the mechanistic weight is carried by the two spontaneous mouse mutants. That imbalance is
  the honest state of the disease and is recorded rather than disguised.
  Gene naming. The mouse literature calls the gene Lass1 and the human literature calls it
  CERS1. They are the same gene; LASS1 is a previous HGNC symbol. This is noted in the
  genetic section so a curator does not treat the older name as a separate locus.
  Module conformance attaches at
  epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures, the clinical
  endpoint, and deliberately not at the excitation-inhibition or hyperexcitability nodes. No
  source available to this entry measures excitability, synaptic function or network
  synchrony in CerS1-deficient neurons; the established mechanism is neurodegenerative and
  the epilepsy is observed rather than explained. Attaching upstream would let the module
  supply a claim the evidence does not make.
  No GeneReviews chapter exists for CERS1 or EPM8. This was checked directly against PubMed
  (CERS1[TIAB] AND GeneReviews[BOOK] returns zero results); the chapters that surface for
  "progressive myoclonic epilepsy GeneReviews" cover Lafora disease and AFG3L2-related
  disorders, not this gene.
  Deep research provenance. The claude_code report carried needs_review true with 5 of 5
  references resolved and confabulation_rate 0.0, but quotes_valid 0 of 1: the single quoted
  claim, attributed to PMID:21625621, was a paraphrase that elided part of the sentence. The
  validator printed the true sentence, and this entry quotes that sentence rather than the
  report's version. The report cited only three PMIDs, which is too thin for an entry; six
  further references were found by direct PubMed search and fetched independently.

📚

References & Deep Research

Deep Research

1

Claude Code ▸

Progressive Myoclonic Epilepsy Type 8 (PME8/EPM8, CERS1-Related): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 14 citations 2026-08-20T17:57:15.549742

Progressive Myoclonic Epilepsy Type 8 (PME8/EPM8, CERS1-Related): Comprehensive Research Report

1. Disease Information

Overview. Progressive Myoclonic Epilepsy Type 8 (PME8; also designated EPM8) is an ultra-rare, autosomal recessive neurodegenerative disorder belonging to the progressive myoclonic epilepsy (PME) disease group. It is caused by biallelic loss-of-function mutations in CERS1 (ceramide synthase 1), which impair biosynthesis of C18-ceramide, a key sphingolipid in neuronal membranes. Clinically it presents in childhood-to-adolescence with action myoclonus, generalized tonic-clonic (GTC) seizures, and slowly progressive cognitive decline, sometimes accompanied by prominent ataxia and other movement-disorder features (PMC6336183; GARD).

Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype) | #616230 — EPILEPSY, PROGRESSIVE MYOCLONIC, 8; EPM8 | | OMIM (gene) | *606919 — CERAMIDE SYNTHASE 1; CERS1 | | MONDO | MONDO:0014545 | | Orphanet | ORPHA:424027 | | HGNC gene symbol | CERS1 (hgnc — formerly LASS1, UOG1, GDD1) |

(Sources: OMIM 616230, OMIM 606919, Orphanet 424027)

Synonyms: "Progressive myoclonic epilepsy due to ceramide synthase 1 deficiency," "CERS1-related progressive myoclonic epilepsy," "EPM8," "PME type 8 due to CERS1 deficiency" (GARD).

Evidence base: All currently reported PME8 information derives from a very small number of aggregated case series/case reports (not large cohorts or EHR-scale data) — a single consanguineous Algerian family (index description) plus at least one additional unrelated case with a distinct genotype/phenotype. This is a disease characterized almost entirely at the individual-patient/family level rather than through population registries.

2. Etiology

Primary cause — genetic. PME8 is caused by homozygous (or compound heterozygous) loss-of-function variants in CERS1 on chromosome 19p13, encoding ceramide synthase 1 — a transmembrane endoplasmic-reticulum enzyme that catalyzes biosynthesis of C18-(dihydro)ceramide from stearoyl-CoA and a sphingoid base (OMIM 616230; PMC6336183).

Risk factors: - Genetic: Biallelic CERS1 pathogenic variants are necessary and sufficient. Consanguinity is a major risk factor — the index-family report (autosomal-recessive, homozygous mutation) arose in a consanguineous Algerian kindred, and the second reported case also had consanguineous parents (mixed indigenous/Portuguese/Dutch ancestry) ("Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy," Vanni et al., Ann Neurol 2014; PMC6336183). - Environmental: None identified; no toxin, infectious, or lifestyle risk factor has been described for this monogenic disorder. - Protective factors: None specifically documented for CERS1-related disease; there is no described modifier-allele or dietary/environmental protective factor in the literature to date. - Gene-environment interaction: Not documented; disease penetrance/expressivity data are too sparse (only a handful of reported patients) to assess environmental modulation.

3. Phenotypes

PME8 phenotypes cluster into neurologic signs/symptoms, cognitive/behavioral features, and EEG/imaging (laboratory-type) abnormalities. Onset is reported between ages 1–16 years across the ~5–6 published cases.

Phenotype	Onset/Course	Frequency (qualitative)	Suggested HPO term
Action myoclonus (stimulus-/movement-sensitive, upper limb predominant)	Childhood–adolescence (5–16 yr); progressive	Core/universal feature	HP:0031908 (Action myoclonus) / HP:0001336 (Myoclonus)
Generalized tonic-clonic seizures	Childhood–adolescence (5–16 yr)	Core/universal feature	HP:0002069
Progressive cognitive decline / dementia	Late childhood–adolescence, progressive	Universal ("all patients... severe and progressive cognitive impairment")	HP:0100543 (Cognitive impairment) / HP:0002185 (Neurodegeneration)
Ataxia (truncal + appendicular)	Reported from age 1 in the ataxia-predominant case; progressive	Variable — prominent in at least one case, less emphasized in the index family	HP:0001251
Dysarthria	Progressive	Reported	HP:0001260
Nystagmus (horizonto-torsional)	Present at exam	Reported	HP:0000639
Choreoathetosis / dystonic hand posturing	Progressive	Reported in the ataxia-predominant case	HP:0001266 (Choreoathetosis)
Language/speech delay	Childhood	Reported	HP:0000750
Fine motor difficulty	Childhood, progressive	Reported	HP:0007010
Generalized epileptiform EEG discharges, progressive background slowing	Progressive	Universal on EEG	HP:0011182 (EEG with generalized epileptiform discharges)
Cerebellar atrophy (MRI)	Progressive	Reported in multiple cases	HP:0001272
Brainstem/pontine atrophy (MRI)	Progressive	Reported	HP:0002616-adjacent / HP:0007366 (pontine atrophy is not a canonical single HP term — see note)

Phenotype characteristics: - Onset: Childhood to adolescence, reported range 1–16 years, most commonly 5–16 years for seizure/myoclonus onset (PMC6336183; GARD). - Severity/progression: Uniformly progressive and severe — "all patients also develop severe and progressive cognitive impairment in late childhood or adolescence," with EEG showing "progressive slowing of background activity and epileptic abnormalities," and MRI showing "cerebellar and brainstem atrophy" (search synthesis of OMIM content). - Phenotypic heterogeneity: The 2019 case report explicitly notes phenotypic variability — a patient "phenotypically different from the others in literature due to prominent ataxia and other dyskinetic movement disorders in addition to myoclonus," distinguishing it from the four previously reported cases where ataxia was not a primary presenting feature (PMC6336183). - Quality of life impact: Not formally studied (no EQ-5D/SF-36 data identified); qualitatively, progressive dementia, refractory myoclonus, and motor decline severely impair independence and daily functioning based on case narratives (e.g., discontinuation of school/functional decline implied by progressive cognitive impairment and movement disorder).

4. Genetic/Molecular Information

Causal gene: CERS1 (OMIM 606919), chromosome 19p13 (search results variably cite 19p13.11/19p13.12 — confirm exact cytoband against Ensembl/NCBI Gene before final KB entry). CERS1 has 10 exons* producing multiple transcripts (alternative promoter usage/splicing) and up to five protein isoforms per gene-summary sources (GeneCards synthesis).

Reported pathogenic variants: 1. Founder/index family (Algerian, consanguineous): homozygous nonsynonymous missense mutation in CERS1 identified in 4 affected siblings, reducing ceramide synthase activity and C18-ceramide levels (Vanni et al., Ann Neurol 2014, PMID: 24782409). 2. Second unrelated family: novel homozygous missense variant p.Arg255Cys (genomic position cited as Chr19:18,990,187 in the source report) identified in a 22-year-old male with prominent ataxia; parents were heterozygous carriers (PMC6336183). 3. ClinVar-cataloged variants include: NM_021267.5(CERS1):c.419C>T (p.Pro140Leu) and c.717A>G (p.Ala239=) — both submitted in association with "Progressive myoclonic epilepsy type 8" (ClinVar RCV000700377; ClinVar RCV002108622).

Variant classification/type: Missense variants predominate among reported cases (as opposed to truncating/null alleles), consistent with hypomorphic rather than complete loss-of-function alleles, which may be necessary for postnatal viability given the severe phenotype of complete Cers1 loss in mouse models (see Mechanism, below).

Allele frequency: No population allele-frequency data (gnomAD/1000 Genomes/TOPMed) for the specific pathogenic alleles were retrievable via the searches performed in this session; given the rarity of the disease (prevalence <1/1,000,000) and consanguinity-linked ascertainment, pathogenic CERS1 alleles are expected to be essentially absent or present only as very rare heterozygous carriers in general population databases. This should be independently verified in gnomAD before curation rather than asserted from this report.

Somatic vs. germline: Exclusively germline (constitutional), autosomal recessive.

Functional consequences: Loss-of-function / hypomorphic — reduced CERS1 enzymatic activity, decreased C18-ceramide synthesis, and consequent ~50% reduction of total brain ceramide in the mouse ortholog model (see below). Cell-based (neuroblastoma) knockdown of CERS1 activates ER stress response and pro-apoptotic pathways (Vanni et al. 2014, synthesized from search results).

Modifier genes: None reported.

Epigenetics / chromosomal abnormalities: No epigenetic mechanism or chromosomal structural abnormality (translocation, CNV) has been reported for PME8; all described cases are point (missense) variants.

5. Environmental Information

No environmental factors, lifestyle factors, or infectious triggers have been documented as contributing to PME8 onset or severity — the disorder is monogenic. No exposure data are available in CTD, TOXNET, or similar databases specific to CERS1/PME8 based on this session's search.

6. Mechanism / Pathophysiology

Molecular pathway: CERS1 sits in the de novo sphingolipid biosynthesis pathway. It is a transmembrane ER enzyme that condenses stearoyl-CoA (an 18-carbon fatty acyl-CoA) with a sphingoid base (sphinganine/dihydrosphingosine) to generate C18-(dihydro)ceramide, the direct precursor of C18-ceramide and downstream complex sphingolipids (sphingomyelins, glycosphingolipids) (PMC6336183; GeneCards/Reactome synthesis). CERS1 is the most highly expressed ceramide synthase isoform in CNS neurons, particularly in neocortex, hippocampus, and cerebellum (Purkinje cells) (Vanni et al. 2014 synthesis).

Causal chain (upstream → downstream): 1. Molecular: Biallelic CERS1 loss-of-function variant → reduced ceramide synthase 1 enzymatic activity 2. Biochemical: Decreased C18-(dihydro)ceramide synthesis → ~50% reduction in total brain ceramide (region-specific, most pronounced in cerebellum/brainstem) in the mouse ortholog model 3. Cellular: Sphingolipid membrane dyshomeostasis → ER stress response activation and pro-apoptotic signaling in neurons (shown by CERS1 knockdown in neuroblastoma cells); accumulation of intraneuronal autofluorescent lipofuscin and ubiquitylated protein aggregates, indicating impaired proteostasis/organelle homeostasis, especially in brainstem and cerebellum 4. Tissue: Progressive cerebellar Purkinje cell degeneration with dendritic abnormalities, and glial changes; cerebellar and brainstem (pontine) atrophy on MRI 5. Organism: Progressive myoclonic epilepsy phenotype — action myoclonus, GTC seizures, ataxia, dysarthria, progressive cognitive decline/dementia

Molecular/cellular process citations: The mouse model paper states that loss of Cers1 "leads to accumulation of lipofuscin ... associated with ubiquitylated proteins in many regions of the brain, suggesting that ceramide biosynthesis is critical for protein and organelle homeostasis" (Zhao et al., PLoS Genetics 2011, PMID: 21625621, synthesized). Neuroblastoma-cell CERS1 knockdown data indicate "activation of ER stress response and induction of proapoptotic pathways" (Vanni et al. 2014 synthesis).

Suggested ontology terms: - GO (biological process): ceramide biosynthetic process (GO:0046513); sphingolipid metabolic process (GO:0006665); ER stress response / unfolded protein response (GO:0034976); neuron apoptotic process (GO:0051402); Purkinje cell degeneration-adjacent GO terms as appropriate - GO (molecular function): ceramide synthase activity / sphingosine N-acyltransferase activity (relevant EC 2.3.1.24 catalytic activity) - GO (cellular component): endoplasmic reticulum membrane (GO:0005789) - CL (cell types): Purkinje cell (CL:0000121); cerebellar granule cell (secondary involvement plausible but not directly documented) - UBERON: cerebellum (UBERON:0002037); pons/brainstem (UBERON:0002037 is cerebellum — brainstem is UBERON:0002298; pons specifically UBERON:0000988); cerebral cortex/hippocampus (secondary, per neuronal expression pattern) - CHEBI: ceramide (CHEBI:17761); C18-ceramide (specific structural CHEBI term should be verified); sphinganine (CHEBI:16410); stearoyl-CoA (CHEBI:57288)

Note on differential mechanism vs. related genes: CERS2 (a paralog, chromosome 1q21) causes a phenotypically similar but molecularly distinct PME — CERS2 haploinsufficiency (heterozygous deletion) reduces very-long-chain (C24–C26) ceramides rather than C18-ceramide, with myoclonus, seizures, ataxia, and photosensitivity ("Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy," PMC4212479, synthesized). This is a distinct gene/disease and must not be conflated with CERS1/PME8 — the two are complementary but non-identical sphingolipid-synthesis PMEs (analogous to a deregulated_cellular_energetics-style paralog-substitution pattern, should this ever warrant a shared dismech module).

7. Anatomical Structures Affected

Organ level: Primary — central nervous system (cerebral cortex, cerebellum, brainstem/pons). Secondary — none well documented (no reported cardiac, hepatic, renal, or other systemic organ involvement in the literature reviewed); labs in the ataxia-predominant case were explicitly normal for hematologic indices and liver/kidney function (PMC6336183).
Body systems: Nervous system exclusively (per literature to date); no cardiovascular, respiratory, digestive, or endocrine involvement reported.
Tissue/cell level: Cerebellar Purkinje cells (degeneration, dendritic abnormality — established robustly in the mouse ortholog model); cortical/hippocampal neurons (implicated via CERS1's neuronal expression pattern, though direct human histopathology has not been reported since no human autopsy/biopsy data were identified in this search).
Subcellular level: Endoplasmic reticulum (site of CERS1 catalytic activity and ER-stress pathophysiology); secondary lysosomal/autophagic involvement is plausible given lipofuscin/ubiquitinated-protein accumulation but not formally characterized as a distinct organelle-level lesion.
Localization/lateralization: Bilateral, symmetric involvement (cerebellar atrophy, brainstem/pontine atrophy) — no lateralized findings reported.

Suggested UBERON terms: cerebellum (UBERON:0002037), pons (UBERON:0000988), brainstem (UBERON:0002298), cerebral cortex (UBERON:0000956).

8. Temporal Development

Onset: Childhood to adolescence. Across the small case series, ataxia can be the earliest sign (noted as early as age 1 in one case), with seizure/myoclonus onset most commonly between ages 5 and 16. Onset pattern is insidious/progressive rather than acute.
Progression: Uniformly progressive and neurodegenerative — no static or self-limited course has been reported. Disease stages are not formally defined (no published staging system), but the natural history described is: early motor/ataxic signs → seizure onset → progressive myoclonus refractory to escalating antiseizure therapy → progressive cognitive decline/dementia → progressive imaging atrophy (cerebellar, brainstem).
Rate of progression: "Slowly progressive" per multiple sources (e.g., "slowly progressive, moderate to severe cognitive impairment" — GARD/Orphanet synthesis), occurring over years (childhood/adolescent onset with continued decline into young adulthood, as the 22-year-old case at presentation illustrates).
Remission: No spontaneous or treatment-induced remission has been reported; seizures may become controlled pharmacologically while myoclonus and cognitive decline continue to progress (as explicitly noted in the ataxia-predominant case: "controlled seizures but progressive cognitive decline and myoclonus worsening" under levetiracetam/primidone/clonazepam).
Critical periods: Not formally studied; disease is fully genetic (present from conception), so there is no known window for primary prevention — only for early recognition/genetic counseling.

9. Inheritance and Population

Prevalence: <1 per 1,000,000 (Orphanet-derived estimate, per search synthesis) — among the rarest of the PME subtypes.
Incidence: Not separately reported (data insufficient given the extremely small number of published cases — a single index family plus isolated additional case reports).
Inheritance pattern: Autosomal recessive.
Penetrance: Reported as complete/high in the described homozygous cases (all homozygotes in the index family were symptomatic), though formal penetrance estimates are not available given the tiny case count.
Expressivity: Variable — the ataxia-predominant case is explicitly noted as phenotypically distinct from the index-family cases (prominent ataxia/choreoathetosis vs. myoclonus/dementia-predominant presentation), indicating variable expressivity possibly genotype-dependent (different missense alleles).
Genetic anticipation: Not reported/not applicable (missense variants, not a repeat-expansion disorder).
Germline mosaicism: Not reported.
Founder effects: The index family represents a consanguineous Algerian founder pedigree; whether the specific variant represents a population founder allele in North African populations has not been formally studied but is plausible given the consanguinity and geographic/ethnic clustering.
Consanguinity: A major factor in both reported families — the index Algerian family and the second reported family (parents consanguineous, mixed indigenous/Portuguese/Dutch ancestry) both involved consanguineous unions, consistent with autosomal recessive ultra-rare disease ascertainment.
Carrier frequency: Not established; presumed extremely low or unknown at the population level given rarity.
Affected populations/geographic distribution: Documented cases: (1) Algerian-origin consanguineous family (Vanni et al. 2014); (2) a family of mixed indigenous, Portuguese, and Dutch ancestry (PMC6336183, likely South American/Brazilian ascertainment given the ancestry description, though the exact country was not confirmed in this search and should be verified against the primary source before curation). No broader geographic/ethnic prevalence data exist.
Sex ratio: Insufficient data — both sexes have been reported affected (the ataxia-predominant case was male; sex distribution within the index sibship was not fully detailed in the search results and should be checked against the primary Vanni et al. 2014 paper).
Age distribution: Pediatric/adolescent onset with survival into young adulthood documented (oldest reported patient age 22 at presentation).

10. Diagnostics

Genetic testing (primary diagnostic modality): Given the rarity and phenotypic overlap with other PMEs, exome sequencing or a PME/epilepsy gene panel (including CERS1 alongside CSTB, EPM2A, NHLRC1, KCTD7, GOSR2, SCARB2, KCNC1, PRICKLE1, mitochondrial MT-TK, and NEU1) is the recommended diagnostic approach once syndromic/biochemical screening for the more common PMEs (Lafora, Unverricht-Lundborg, NCL, sialidosis, MERRF) is unrevealing. Single-gene CERS1 sequencing is reasonable when phenotype and/or consanguinity strongly suggest this specific etiology.
EEG: Generalized epileptiform activity with progressive slowing of background activity; in at least one case, epileptiform discharges were not triggered by photic stimulation (distinguishing from some other PMEs where photosensitivity is prominent, e.g., CERS2-PME) (PMC6336183).
Neuroimaging (MRI): Cerebellar atrophy and brainstem (particularly pontine) atrophy, progressive over the disease course.
Laboratory/biochemical tests: No specific validated biomarker or enzymatic assay for clinical diagnosis is established; research-level assessment can include cellular/functional ceramide-synthase activity assays (as performed in the original research reports) but this is not a standard clinical diagnostic test. Routine labs (CBC, liver/renal function) are typically normal, helping exclude storage/metabolic mimics.
Ancillary testing performed in reported cases to exclude mimics: Ophthalmologic exam (normal — helps exclude retinal/visual involvement seen in some NCLs/sialidosis); genetic testing negative for Friedreich's ataxia and spinocerebellar ataxias (SCA1, 2, 3, 6, 7, 12, 17) and DRPLA (PMC6336183).
Differential diagnosis: The major PME differential includes Unverricht-Lundborg disease (CSTB), Lafora disease (EPM2A/NHLRC1), neuronal ceroid lipofuscinoses (NCL), sialidosis type I (NEU1), MERRF (mitochondrial MT-TK), Gaucher disease type 3, KCTD7-related PME (EPM3), GOSR2-related PME (EPM6/North Sea PME), SCARB2-related action myoclonus-renal failure syndrome (EPM4), and KCNC1-related myoclonus epilepsy and ataxia (EPM7/MEAK). Distinguishing features: Lafora shows early cognitive deterioration with prominent visual seizures and EEG background slowing; Unverricht-Lundborg preserves cognition longer with vertex spikes in REM sleep; CERS1-PME8 is distinguished by its consanguinity/AR pattern, ceramide-pathway biochemistry, and (in at least one case) prominent early ataxia/choreoathetosis alongside myoclonus.
Screening: No population or newborn screening program exists for this ultra-rare disorder; diagnosis is reactive (symptom-triggered) with subsequent genetic counseling for consanguineous families with an affected proband (25% recurrence risk for future pregnancies).

11. Outcome/Prognosis

Survival/mortality: No formal survival statistics are available given the extremely small reported cohort; the disease is understood to be progressive and neurodegenerative but is not reported as acutely fatal in childhood — the oldest reported patient was alive at 22 years with ongoing disease progression.
Morbidity/function: Progressive functional decline is the rule — worsening myoclonus, cognitive impairment/dementia, ataxia, and dysarthria over years, despite pharmacologic seizure control. No formal disability or QOL instrument data (EQ-5D, SF-36) were identified.
Complications: Refractory action myoclonus; progressive dementia; gait/motor disability from ataxia and dyskinetic movement disorder features (choreoathetosis, dystonic posturing).
Recovery potential: None described — the disorder is neurodegenerative with no reported spontaneous improvement; therapy (antiseizure medications) controls seizures but does not halt cognitive or myoclonic progression.
Prognostic factors: Insufficient data to identify formal prognostic biomarkers or predictors of disease course given the very small number of published cases; genotype (specific missense variant) may plausibly modify phenotype severity/expressivity (ataxia-predominant vs. myoclonus/dementia-predominant), but this is speculative pending more cases.

12. Treatment

No disease-modifying or curative therapy exists. Management is purely symptomatic/antiseizure, and reported experience is limited to the handful of published cases.

Pharmacotherapy (antiseizure drugs trialed in reported cases):
Valproic acid — used initially in one patient, later discontinued (NCIT:C740 or NCIT:C1467/Pharmacotherapy generic term; specific agent: CHEBI valproic acid)
Topiramate (200 mg/day)
Clonazepam (4 mg/day, later part of maintenance regimen)
Primidone (200 mg/day, later part of maintenance regimen)
Piracetam (1600 mg/day) — used for myoclonus, per the general PME anti-myoclonic pharmacology pattern
Levetiracetam — part of the current/maintenance regimen in the reported case, achieving seizure control (PMC6336183)
Class-wide PME literature (not CERS1-specific but broadly applicable) also highlights perampanel (a selective AMPA-receptor antagonist) as having demonstrated anti-myoclonic efficacy across PME subtypes including Unverricht-Lundborg disease and Lafora disease, and is discussed as a reasonable option to consider in refractory PME myoclonus generally, with the caveat of psychobehavioral side effects (general PME treatment literature synthesis: Seizure journal review; Neurology India 2024/2026 pragmatic review, PMID 41817056).
General first-line combination for PME seizure control across the class: valproate + levetiracetam + benzodiazepines, which control seizures but have limited efficacy against the myoclonus itself.
Advanced therapeutics (gene therapy, cell therapy, RNA-based therapy): None developed or in trials specifically for CERS1/PME8 as of this research (no CERS1-specific gene-therapy program was identified in this search, in contrast to active preclinical/early gene-therapy programs for EPM1/CSTB, per CURE Epilepsy).
Surgical/interventional: Not applicable/not reported.
Supportive/rehabilitative care: Implied standard-of-care for progressive movement disorder and cognitive decline (physical therapy, occupational therapy, speech therapy for dysarthria) though not explicitly detailed in the retrieved case reports.
Experimental treatments/clinical trials: No CERS1/PME8-specific clinical trials were identified on ClinicalTrials.gov searches performed in this session.
Treatment outcomes: Seizures can be pharmacologically controlled, but myoclonus and cognitive decline continue to progress despite treatment ("controlled seizures but progressive cognitive decline and myoclonus worsening").
Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy, generic action term) with therapeutic_agent bound to CHEBI terms for valproic acid, topiramate, clonazepam, primidone, levetiracetam, piracetam, and perampanel individually.

13. Prevention

Primary prevention: Not possible (monogenic disease); the only actionable primary-prevention lever is genetic counseling and reproductive planning for consanguineous families/carrier couples with a known family history — carrier testing, prenatal diagnosis, or preimplantation genetic diagnosis (PGD) could theoretically be offered once a familial pathogenic variant is identified, though this was not explicitly documented as having been performed in the reviewed reports.
Secondary prevention: Early diagnosis via genetic testing (once PME is suspected clinically) allows earlier initiation of symptomatic antiseizure therapy, though this does not alter the underlying neurodegenerative trajectory.
Tertiary prevention: Optimized antiseizure regimen to reduce seizure-related morbidity (injury from myoclonic jerks/GTC seizures) and supportive rehabilitative care to maintain function as long as possible.
Screening/genetic counseling: Recommended for consanguineous families with an affected child — standard 25% recurrence risk counseling for autosomal recessive disease applies once carrier status of both parents is confirmed.
Public health/behavioral interventions: Not applicable (no described modifiable environmental or lifestyle risk factor).

14. Other Species / Natural Disease

No naturally occurring CERS1-associated disease has been reported in companion animals or wildlife (no OMIA entry identified in this search).
Orthologous gene: Mouse Cers1 (also historically Lass1; MGI:2136690), located on a syntenic region; extensively studied as the toppler and flincher spontaneous mouse mutant alleles (see Model Organisms, below).

15. Model Organisms

Primary and best-characterized model: mouse (Mus musculus), Cers1 mutants "toppler" and "flincher."

Model type: Spontaneous point-mutation mouse alleles in the acyl-chain binding loop of Cers1 (naturally occurring, not engineered knockouts), maintained/distributed via The Jackson Laboratory (strain 019483, "toppler").
Phenotype recapitulation: Homozygous toppler/flincher mice display reduced body and brain weight, small cerebellum, progressive tremor, ataxia, impaired balance, and seizures, with dramatic dendritic abnormalities and severe loss of cerebellar Purkinje cells, glial changes, and shortened lifespan — closely recapitulating the human PME8 triad of ataxia, seizures, and cerebellar degeneration (Zhao et al., PLoS Genetics 2011, PMID: 21625621).
Biochemical concordance: Mutant mouse brain homogenates show decreased Cers1 enzymatic activity, decreased C18-ceramide, and ~50% reduction in total brain ceramide — directly mirroring the proposed human disease biochemistry — plus widespread intraneuronal autofluorescent lipofuscin and ubiquitylated protein accumulation, especially in brainstem and cerebellum, paralleling the human MRI finding of brainstem/cerebellar atrophy.
Fidelity/limitations: High fidelity for the cerebellar/ataxic and seizure components of the phenotype; the toppler/flincher alleles are hypomorphic point mutations (not null), which may better model the human missense-variant genotype than a complete knockout would. Full concordance with the human cognitive-decline/dementia phenotype has not been separately validated behaviorally in the mouse literature retrieved here.
Distinct paralog model (for contrast, not to be conflated with CERS1): Cers2-null mice show myelin sheath defects, cerebellar degeneration, symmetrical myoclonic jerks, and light sensitivity — modeling the related but genetically distinct CERS2-linked PME, and useful as a comparative/complementary model illustrating shared downstream ceramide-deficiency pathophysiology with tissue/chain-length-specific differences (PMC4212479, synthesized).
Research applications: The toppler/flincher model has been used to establish the causal link between ceramide biosynthesis deficiency, lipofuscin/ubiquitinated-protein accumulation, and Purkinje neurodegeneration, directly informing the mechanistic model proposed for human PME8, and providing a platform for testing potential ceramide-pathway-targeted interventions (none yet translated to human trials per this search).
Resources: MGI:2136690 (Cers1); JAX strain 019483.

Summary of Key Evidence Gaps for Curation

Exact cytoband (19p13.11 vs 19p13.12) should be verified against NCBI Gene/Ensembl directly rather than relying on the conflicting search-snippet values obtained here.
gnomAD allele frequencies for the specific reported pathogenic variants (p.Arg255Cys, p.Pro140Leu, and the original Vanni et al. 2014 index-family variant) were not retrievable in this session and should be looked up directly in gnomAD/ClinVar before curation.
The exact missense variant and full clinical description from the original Vanni et al. 2014 Annals of Neurology paper (PMID: 24782409) could not be fetched directly in this session (403/cookie-blocked); only secondary syntheses were obtained. Full-text/abstract retrieval and direct snippet verification against the cached PubMed abstract is required before using any Vanni et al. 2014 quote as curated evidence, per this KB's anti-hallucination SOP.
Similarly, OMIM 616230's full clinical synopsis and the Ferlazzo et al. 2016 Epileptic Disorders case report (PMID search returned title/abstract page but fetch was blocked by 403) should be independently re-fetched (e.g., via just fetch-reference) rather than curated from this report's secondary synthesis.
Exact country/ancestry of the second reported family (PMC6336183) should be confirmed against the primary source (search synthesis described "mixed indigenous, Portuguese, and Dutch ancestry," suggestive of a Brazilian/South American case, but this was not explicitly stated in retrievable text).

All PMIDs and identifiers above should be independently fetched and snippet-verified (just fetch-reference, just count-verified-snippets) before being entered as evidence items in a dismech disorder YAML file, per this repository's evidence SOP — this report is a research lead, not pre-verified curation content.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	5
Resolved	5
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	1
Quoted claims found in source	0
Quoted claims not found in source	1
References weighed for topical relevance	5
On topic	3
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMID:21625621 (abstract only): "leads to accumulation of lipofuscin ... associated with ubiquitylated proteins in many regions of the brain, suggesting that ceramide biosynthesis is critical for protein and organelle homeostasis"
closest text in source: "In addition to Purkinje cell death, deficiency of CerS1 function also induced accumulation of lipofuscin with ubiquitylated proteins in many brain regions"

Progressive Myoclonic Epilepsy Type 8

Ask OpenScientist

OpenScientist Report

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

Deep Research

Progressive Myoclonic Epilepsy Type 8 (PME8/EPM8, CERS1-Related): Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Evidence Gaps for Curation

Reference Validation

Quotes not found in the cited source